Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dispenzieri

Showing results (131-140 of 154) with videos related to

Pageof 16
Sort By:
Bone Marrow Transplantation|May 4, 2010
Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilizationH V Naina, R K Pruthi, D J Inwards, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Leukemia Research|August 23, 2005
Ploidy status rarely changes in myeloma patients at disease progressionW J Chng, J M Winkler, P R Greipp, et al.
Leukemia|December 2, 2016
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryE Muchtar, A Dispenzieri, S K Kumar, et al.
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
British Journal of Haematology|January 16, 2007
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosisE M Ocio, R F J Schop, B Gonzalez, et al.
Leukemia|July 27, 2016
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progressionW I Gonsalves, S V Rajkumar, A Dispenzieri, et al.
Pageof 16

Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Bone Marrow Transplantation|May 4, 2010
Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilizationH V Naina, R K Pruthi, D J Inwards, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Leukemia Research|August 23, 2005
Ploidy status rarely changes in myeloma patients at disease progressionW J Chng, J M Winkler, P R Greipp, et al.
Leukemia|December 2, 2016
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryE Muchtar, A Dispenzieri, S K Kumar, et al.
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
British Journal of Haematology|January 16, 2007
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosisE M Ocio, R F J Schop, B Gonzalez, et al.
Leukemia|July 27, 2016
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progressionW I Gonsalves, S V Rajkumar, A Dispenzieri, et al.
Pageof 16